Literature DB >> 2144747

Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma.

O Merimsky1, I Reider-Groswasser, M Inbar, S Chaitchik.   

Abstract

Five out of 38 patients (13%) with metastatic renal cell carcinoma had mental deterioration 3 weeks to 13 months after the start of treatment with recombinant interferon alpha-C. Metastatic spread to the brain, paraneoplastic effect of the tumor on the central nervous system and other causes of dementia were excluded. Computed tomography of the brain in these patients was normal and the width of the cerebral sulci and ventricles did not correlate with the severity of dementia. Specific patterns of atrophy were not seen. General deterioration, assessed by the change in Karnofsky performance status, was associated with dementia. The dementia may have been caused by a neurotoxic effect of interferon.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144747     DOI: 10.1016/0277-5379(90)90086-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Side effects of interferon-alpha therapy.

Authors:  Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Journal:  Pharm World Sci       Date:  2005-12

2.  Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test.

Authors:  M Makino; Y Kitano; C Komiyama; M Hirohashi; K Takasuna
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 3.  Drug-induced dementia. Incidence, management and prevention.

Authors:  J M Starr; L J Whalley
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 4.  Neuropsychiatric side effects of interferon-alfa therapy.

Authors:  Arthur R Van Gool; Wim H J Kruit; Frederike K Engels; Gerrit Stoter; Marjolein Bannink; Alexander M M Eggermont
Journal:  Pharm World Sci       Date:  2003-02

Review 5.  Central nervous system toxicity from cancer treatment.

Authors:  Terri Armstrong; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

Review 6.  Interferon-related cortical blindness.

Authors:  O Merimsky; P Nisipeanu; A Loewenstein; I Reider-Groswasser; S Chaitchik
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 7.  Drug-induced depression. Incidence, avoidance and management.

Authors:  S B Patten; E J Love
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

Review 8.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

9.  Major depression during interferon-alpha treatment: vulnerability and prevention.

Authors:  Francis E Lotrich
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.